What are the adverse effects of dipeptidyl peptidase IV inhibitors (DPP-4 inhibitors) in the treatment of type 2 diabetes mellitus (DM)?

Updated: May 14, 2020
  • Author: Romesh Khardori, MD, PhD, FACP; Chief Editor: George T Griffing, MD  more...
  • Print

Upper respiratory tract infections have been increasingly reported among users of DPP-4 inhibitors compared with users of other antidiabetic drugs. [203] However, further research is needed to evaluate the scope and underlying mechanisms of this phenomenon. On the other hand, a meta-analysis suggested that treatment with DPP-4 inhibitors could reduce the risk of bone fractures. [204]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!